The Breast International Group (BIG)
The European Society for Medical Oncology (ESMO)
The European Organisation for Research and Treatment of Cancer (EORTC)
Europa Donna
Foundation “St.Gallen Oncology Conferences” (SONK)
IMPAKT 2013 Officers
1PDEDICATED BREAST PET-CT FOR THE ASSESSMENT OF BREAST TUMORS : AN ALTERNATIVE FOR PATIENTS UNSUITABLE FOR CE-MRI?
2PA HIGH FREQUENCY OF MUTATIONS IS IDENTIFIED IN A SINGLE EXON OF THE CHEK2 GENE IN GREEK BREAST/OVARIAN PATIENTS
3PFACTORS INFLUENCING AGREEMENT BETWEEN CORE NEEDLE BIOPSY AND SURGICAL RESECTION SPECIMENS REGARDING KI67 LABELING INDEX – RESULTS OF A RETROSPECTIVE ANALYSIS
4PVALIDATION OF BRCA MUTATION-CARRIER PROBABILITY MODEL, BRCAPRO IN THE JAPANESE POPULATION
5PINTERPRETING GENOMIC DIVERSITY FOR BREAST CANCER : MOLECULAR SUBTYPES OF BREAST CANCER IN VERY YOUNG WOMEN (≤35 Y) IN WESTERN TURKEY
6PA MAJORITY OF BREAST CANCER SPECIMENS WITH 1-9 % ER POSITIVITY BEHAVE LIKE HORMONE RECEPTOR NEGATIVE TUMORS
7PDETECTION AND QUANTITATION OF CIRCULATING TUMOR CELLS, CANCER STEM CELLS AND ENDOTHELIAL PROGENITOR CELLS USING MULTIPARAMETER FLOW CYTOMETRY
8PDIAGNOSTIC NEXT-GENERATION SEQUENCING PANEL FOR HEREDITARY BREAST AND OVARIAN CANCER
10PMORE FREQUENT SCREENING OF THE CONTRALATERAL BREAST IS WARRANTED AFTER TREATMENT OF PRIMARY NODE-POSITIVE BREAST CANCER
11PPREVENTIVE DIAGNOSTICS OF BREAST CANCER
12PPREDICTIVE VALUE OF POSITIVE AXILLARY LYMPH NODE FINE NEEDLE ASPIRATION IN PRIMARY BREAST CANCER
9PEVALUATION OF MAMMAGLOBIN TRANSCRIPTION AND PROTEIN IN BLOOD AS A MARKER FOR DIAGNOSIS OF BREAST CANCER
89OUSE OF LIVE IN-VIVO LYMPHATIC IMAGING TECHNIQUES TO STUDY THE EFFECTS OF IMMUNE CELL INTERACTIONS IN A SYNGENEIC MOUSE MODEL OF BREAST CANCER
90OGE226 : A MOLECULAR TARGETED PET IMAGING AGENT TO ASSESS HER2 STATUS IN VIVO
91OEARLY EFFECT OF PI3K-AKT-MTOR BLOCKADE ON IN VITRO 18F-FDG UPTAKE IN HER2+ BREAST CANCER RESISTANT TO TRASTUZUMAB
92PAPPARENT DIFFUSION COEFFICIENT - A NON-INVASIVE BIOMARKER FOR THE INVASIVENESS OF BREAST CANCER
93PASSESSMENT OF RESPONSE TO NEOADJUVANT CHEMOTHERAPY WITH DIFFUSION WEIGHTED IMAGING AT 3T
94PEVALUATION OF OXYGENATION IN BREAST CANCERS BY PHOTOACOUSTIC MAMMOGRAPHY : CLINICAL AND HISTOLOGICAL COMPARISON
95PINFRARED IMAGING : A POTENTIAL NEW TOOL TO CHARACTERIZE LYMPHOCYTIC INFILTRATION IN HUMAN BREAST CANCER
96PUSING FOURIER-TRANSFORMED INFRARED (FTIR) SPECTROSCOPIC IMAGING AND PRINCIPAL COMPONENT ANALYSIS - FUZZY C-MEANS (PCA-FCM) FOR IMPROVEMENT ON BREAST CANCER PROGNOSIS
13PPRELIMINARY RESULTS OF “BONADIUV” TRIAL : A SINGLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY DESIGNED TO EVALUATE THE IMPACT OF BISPHOSPHONATE TREATMENT ON BONE MINERAL DENSITY IN OSTEOPENIC WOMEN TAKING AROMATASE INHIBITORS
14PIMPROVING OUTCOMES BY THE ADDITION OF SEQUENTIAL PACLITAXEL TO DOXORUBICIN/CYCLOPHOSPHAMIDE IN AN ADJUVANT CHEMOTHERAPY REGIMEN FOR PATIENTS WITH NODE-POSITIVE PRIMARY BREAST CANCER
15PADJUVANT TRASTUZUMAB IN HER2-POSITIVE BREAST CANCER : OBSERVATIONAL MONOCENTRIC STUDY OF 84 CASES
16PPREDICTION MODEL FOR NONSENTINEL LYMPH NODE STATUS IN BREAST CANCER PATIENTS WITH METASTATIC SENTINEL LYMPH NODES
17PFREQUENCY OF PATHOLOGICAL COMPLETE RESPONSE WITH ADRIAMYCIN AND TAXANES BASED NEO-ADJUVANT CHEMOTHERAPY IN NON-METASTATIC BREAST CANCER
18PRADIATION TREATMENT PLANNING IN POSTMASTECTOMY PATIENTS - COMPARISON OF 3D VERSUS 2D PLANS
19LYMPHEDEMA IN PATIENTS WITH BREAST CANCER UNDERGOING SURGERY AND RADIOTHERAPY
20PNCI 8609 : MULTICENTER PHASE I TRIAL OF PARP INHIBITOR VELIPARIB WITH CARBOPLATIN IN ADVANCED BREAST CANCER
21PTRASTUZUMAB BEYOND PROGRESSION FOR METASTATIC HER2+ BREAST CANCER (MBC) : SURVIVAL OUTCOMES IN A CANADIAN POPULATION
22PTHE POSSIBLE RESOLUTION OF TAMOXIFEN-INDUCED HOT FLASH BY COMBINATION WITH RISPERIDONE IN BREAST CANCER PATIENTS WITHOUT INTERFERING WITH THE EFFICACY OF TAMOXIFEN
23PINCREASED ANTICANCER EFFICACY BY THE COMBINED ADMINISTRATION OF QUERCETIN IN MULTIDRUG RESISTANT BREAST CANCER CELLS
24PSYNTHESIS, CHARACTERIZATION AND IN VITRO ANTICANCER ACTIVITY OF DOX-LOADED COPPER OXIDE NANOPARTICLES TARGETING BREAST CANCER
25PAROMATASE INHIBITOR AND CAPECITABINE AS 1ST OR 2ND LINE TREATMENT IN METASTATIC BREAST CANCER – A RETROSPECTIVE ANALYSIS
26PMETAPLASTIC BREAST CANCER : A RETROSPECTIVE ANALYSIS
27NEOADJUVANT CHEMOTHERAPY (NAC) FOR BREAST CANCER - PRELIMINARY EXPERIENCE FROM A TERTIARY CANCER CENTER IN INDIA
28LAPATINIB IN EGYPTIAN WOMEN WITH METASTATIC BREAST CANCER : IN WHICH DOSE AND AT WHAT FREQUENCY?
29PGENOMIC ANALYSIS OF DRUG RESISTANT TRIPLE NEGATIVE BREAST CANCERS : A TRANSLATIONAL BIOPSY STUDY
30PIDENTIFICATION OF A SPECIFIC GENE SIGNATURE PREDICTIVE OF RESPONSE TO BEVACIZUMAB IN PATIENTS WITH TRIPLE-NEGATIVE INFLAMMATORY BREAST CANCER
31PGAIN OF CHROMOSOMAL REGION 15Q26 CAUSE INCREASED EXPRESSION OF BLM AND FANCI, AND IS ASSOCIATED WITH SENSITIVITY TO PLATINUM CHEMOTHERAPY IN TRIPLE NEGATIVE BREAST CANCER
32PTHERAPEUTIC TARGETING OF TRIPLE NEGATIVE BREAST CANCER WITH COMBINATORIAL INHIBITION OF NOTCH AND RAS/MAPK PATHWAY
33PTHE PIM1 KINASE SHOWS GENOME DRIVEN UPREGULATION, SUPPRESSES APOPTOSIS, ENABLES COLONY FORMATION AND CELL MIGRATION AND IS A POTENTIAL TARGET IN TRIPLE-NEGATIVE BREAST CANCER
34PPROFILING STEM CELLS IN TRIPLE NEGATIVE BREAST CANCER - A PCR-ARRAY-BASED STUDY
35PEXPRESSION OF THE 4Q12 CHROMOSOMAL GENES KIT, VEGFR2 AND PDGFRα IN TRIPLE-NEGATIVE BREAST CANCER
36PANDROGEN RECEPTOR EXPRESSION IN BREAST CANCER WITH SPECIAL RELATION TO TRIPLE-NEGATIVE MOLECULAR PHENOTYPE AND ITS RESPONSE TO ANTERIOR CHEMOTHERAPY
38PRELATION BETWEEN BMI AND MORPHOLOGICAL CHARACTERISTICS TRIPLE-NEGATIVE BREAST CANCER
39AN EXTREME PHENOTYPIC EXPRESSION OF A RARE BRCA1 MUTATION IN A FEMALE DIAGNOSED WITH EARLY ONSET TRIPLE NEGATIVE BREAST CANCER
37PBRAIN METASTASES IN TRIPLE RECEPTOR-NEGATIVE BREAST CANCER : FREQUENCY, RISK GROUPS AND PROGNOSIS
40O_PRCONTRIBUTION OF ANALYTICAL, PRE-ANALYTICAL AND INTRA-TUMORAL HETEROGENEITY TO VARIANCE IN GENE EXPRESSION MEASUREMENTS FROM HUMAN BREAST CANCERS
41O_PRHETEROGENEITY OF GENOMIC SIGNATURES IN BREAST CANCER CORE BIOPSY
42O_PRASSESSMENT OF GENETIC ALTERATIONS IN POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER FROM THE BOLERO-2 TRIAL BY NEXT-GENERATION SEQUENCING
43PEFFECTS OF MTOR INHIBITION ON IR/IGF-1R SIGNALLING IN PIK3CA-MUTATED, TAMOXIFEN RESISTANT BREAST CANCER
44PUNRAVELLING THE EFFECT OF ESTROGEN ON BREAST CANCER CELL PROTEOME USING QUANTITATIVE PROTEOMICS
45PDECIPHERING PATTERNS OF CHROMOSOMAL ABERRATIONS IN BREAST CANCER PATIENTS : HOW DEFECTS IN SPECIFIC DNA REPAIR GENES AFFECT THE ACCUMULATION OF GROSS DNA ABERRATIONS IN THE CANCER GENOME
46PAN 11 GENE Q-PCR ASSAY TO SUB-STRATIFY BREAST TUMORS INTO CATEGORIES USEFUL IN DECIDING ANTI-HER-2 THERAPIES
49PCHANGES IN GENE EXPRESSION PROFILES FOLLOWING PRE-SURGICAL STATIN TREATMENT IN A WINDOW-OF-OPPORTUNITY BREAST CANCER TRIAL
50PASSOCIATION OF ESR1 POLYMORPHISMS WITH TAMOXIFEN RESPONSE IN WOMEN WITH ESTROGEN RECEPTOR-POSITIVE BREAST CANCER
47PGENOME-WIDE DNA COPY NUMBER PROFILES IDENTIFY LAPATINIB SENSITIVITY IN METASTATIC BREAST CANCER PATIENTS
48PGENETIC AND EPIGENETIC HETEROGENEITY OF PUTATIVE BREAST CANCER STEM CELLS
51PBREAST CANCER HETEROGENEITY : THE POTENTIAL ROLE OF MALDI IMAGING MASS SPECTROMETRY IN SUBTYPING
52PSIRT1 AS A POTENTIAL THERAPEUTIC TARGET IN BREAST CANCER
53O_PRPREDICTING RISK FOR LATE METASTASIS : THE PAM50 RISK OF RECURRENCE (ROR) SCORE AFTER 5 YEARS OF ENDOCRINE THERAPY IN POSTMENOPAUSAL WOMEN WITH HR+ EARLY BREAST CANCER
54O_PRCOMPARISON OF FIVE DIFFERENT SCORES FOR THE PREDICTION OF LATE RECURRENCE FOR OESTROGEN RECEPTOR-POSITIVE BREAST CANCER
55O_PRPROGNOSTIC AND PREDICTIVE VALUE OF IHC4 AND ERB1 IN THE INTERGROUP EXEMESTANE STUDY (IES) - ON BEHALF OF THE PATHIES INVESTIGATORS
56O_PRPREDICTIVE VALUE OF AKT/MTOR PATHWAY IMMUNOHISTOCHEMICAL (IHC) BIOMARKERS FOR RESPONSE TO PREOPERATIVE TRASTUZUMAB (T) VS TRASTUZUMAB + EVEROLIMUS (T + E) IN PATIENTS (PTS) WITH EARLY BREAST CANCER (BC) : UNICANCER RADHER TRIAL RESULTS
57PRELATIONSHIP OF PIK3CA MUTATION AND PI3K PATHWAY ACTIVITY WITH ANTIPROLIFERATIVE RESPONSE TO ANASTROZOLE IN ER+ BREAST CANCER
58PEVALUATION OF BREAST CANCER TEST-TREATMENT STRATEGIES USING DECISION-ANALYTIC MODELING – PRELIMINARY RESULTS FOR THE 21-GENE ASSAY RECURRENCE SCORE
59PHEALTH ECONOMIC ANALYSIS OF GUIDELINE AND GENE EXPRESSION SIGNATURE-BASED RISK STRATIFICATION OF DISTANT RECURRENCE IN EARLY BREAST CANCER PATIENTS
60PIDENTIFICATION OF SNPS ASSOCIATED TO RESPONSE OF BREAST CANCER PATIENTS TO NEO-ADJUVANT CHEMOTHERAPY IN THE EORTC-10994 / BIG1-00 RANDOMISED PHASE III TRIAL
61PIDENTIFICATION OF BRCANESS IN SPORADIC BREAST CANCERS USING A MODEL THAT INTEGRATES MULTIPLE ASSAYS
62PBRCA1 4153DELA AND 5382INSC MUTATIONS CONFER DIFFERENT RISKS OF CONTRALATERAL BREAST AND SECOND PRIMARY MALIGNANCIES IN BREAST CANCER PATIENTS
63PSERUM THYMIDINE KINASE ACTIVITY COMPARED WITH CA 15-3 IN LOCALLY ADVANCED AND METASTATIC BREAST CANCER AS PART OF A PROSPECTIVE AND RANDOMIZED STUDY
64PCHARACTERISTICS OF PATIENTS WITH BREAST CANCER (BC) BRAIN METASTASES (BM) : ARE THERE ANY CLUES FOR EARLIER BM DIAGNOSTIC STRATEGIES?
65PSERUM HER-2 LEVELS AS A PREDICTOR OF CLINICAL OUTCOME IN METASTATIC BREAST CANCER (MBC) PATIENTS TREATED WITH TRASTUZUMAB-BASED THERAPIES
66PALLELIC IMBALANCE AT THE HER2/TOP2A LOCUS IN BREAST CANCER
67PDELETIONS AT 1P13.3 IS ASSOCIATED WITH SIGNIFICANTLY ADVERSE PROGNOSIS IN BREAST CANCER
68PEXPRESSION OF SRC KINASE FAMILY MEMBERS IN TAMOXIFEN TREATED ER POSITIVE BREAST CANCER AND ASSOCIATION WITH CLINICAL OUTCOME
69PA NOVEL MULTIGENE ASSAY IN CLINICAL PRACTICE - PERFORMANCE AND IMPACT ON CLINICAL DECISIONS
70PPREDICTIVE VALUE OF BONE MARROW MICROMETASTASIS DETECTED BY NESTED RT-PCR FOR CYTOKERATIN-19 IN BREAST CANCER PATIENTS
71PMOLECULAR ANALYSIS OF SINGLE CIRCULATING TUMOR CELLS (CTCS) ISOLATED FROM METASTATIC BREAST CANCER (MBC) PATIENTS (PTS)
72PBAG-1 IN CORE BIOPSIES, TISSUE MICROARRAYS AND SURGICAL SAMPLES– INVESTIGATION OF A NOVEL APOPTOSIS BIOMARKER IN TWO INDEPENDENT BREAST CANCER COHORTS
73PEXPRESSION OF PHOSPHORYLATED PROTEINS FROM PI3-KINASE AND MAP-KINASE SIGNALING PATHWAYS IN INFILTRATING BREAST CANCER : RELATION WITH HISTOPATHOLOGIC AND MOLECULAR SUBTYPES
74PDETECTION OF ABERRANT METHYLATION GENES IN PLASMA DNA AS PREDICTOR OF THERAPEUTIC OUTCOME OF PATIENTS WITH BREAST CANCER
75PEXPRESSION OF XIST AND 53BP1 AS PREDICTIVE MARKERS IN BRCA1 DEFICIENT BREAST CANCER
76PSEROLOGICAL DETECTION OF MATRIX METALLOPROTEINASE GENERATED FRAGMENTS OF ELASTIN AND TYPE IV COLLAGEN MAY BE BIOMARKERS OF LUNG METASTATIC BREAST CANCER
77PPROGNOSTIC VALUE OF A FOUR-MARKER PANEL ASSOCIATED WITH BREAST CANCER-SPECIFIC SURVIVAL
78PCLINICAL IMPLICATION OF SMAD4 EXPRESSION AS PROGNOSTIC MARKER IN BREAST CANCER
79PMRI BREAST DENSITY ASSESSMENT : AN IMAGING BIOMARKER FOR IDENTIFICATION OF WOMEN AT AN INCREASED RISK OF BREAST CANCER
80PUSE OF MARKERS OF BONE TURNOVER (CTX AND P1NP) FOR MONITORING THE RESPONSE TO THERAPY BONE METASTASES BREAST CANCER
81PCOMBINATION OF PROLIFERATIVE ACTIVITY AND ENERGY LEVEL CHANGES TO PREDICT THE MALIGNANCY AND TREATMENT RESPONSE IN INVASIVE BREAST CANCER PATIENTS
82PPLASMA PRONEUROTENSIN AS A NOVEL BIOMARKER FOR THE PREDICTION OF INCIDENT BREAST CANCER
83PIMMUNOHISTOCHEMICAL DETECTION OF BRCA 1 PROTEIN AND PTEN PROTEIN IN INVASIVE DUCTAL BREAST CANCER
84OCXCL13-PRODUCING FOLLICULAR HELPER CD4+ T CELLS IN EXTENSIVELY-INFILTRATED BREAST CANCER SIGNAL AN ORGANIZED IMMUNE RESPONSE AND PREDICT SURVIVAL
85PUPREGULATION OF IL15RA IN TRIPLE NEGATIVE BREAST CANCER (TNBC) PROMOTES TUMOUR CELL GROWTH AND MOTILITY AND CAN ACTIVATE AN IMMUNE CELL RESPONSE
86PTHE COMPOSITION AND ORGANIZATION OF LYMPHOCYTES INFILTRATING HUMAN BREAST CANCER
87PCHEMOTHERAPY-INDUCED PROTRACTED CHANGES TO INFLAMMATORY IMMUNE POTENTIAL
88PCLINICAL STAGE-DEPENDENT DOWN-REGULATION OF STAT 1, 3 AND 5 EXPRESSION AND INDUCTION BY TH1 CYTOKINES IN BREAST CANCER PATIENTS
97PAT-101 (-/- GOSSYPOL) IN COMBINATION WITH TRASTUZUMAB TRIGGERS APOPTOSIS THROUGH INHIBITING BCL-2, BCL-XL AND MCL-1 PROTEIN LEVELS IN HUMAN HER2-POSITIVE BREAST CANCER CELLS
98PEZH2 PROMOTES A PROGENITOR-LIKE BI-LINEAGE DIFFERENTIATION STATE IN BASAL-LIKE BREAST CANCER CELLS
99PSIMULTANEOUS, MULTICOLOUR SINGLE MOLECULE IMAGING OF THE ENTIRE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR (HER) FAMILY IN LIVE BREAST CANCER CELLS
100PBRCA1 INACTIVATION INDUCES ALTERNATIVE NF-κB PATHWAY ACTIVATION IN HUMAN BREAST CANCER CELLS AND MAMMARY GLANDS
101PTHE PRESENCE OF ALVEOLAR STRUCTURES IN BREAST TUMORS IS ASSOCIATED WITH DRUG RESISTANCE GENE UPREGULATION AND POOR CHEMOTHERAPY RESPONSE
102PIS IT POSSIBLE TO TAILOR BREAST CANCER TREATMENT BY USING BREAST CANCER STEM CELLS AS A CELL MODEL?
103PIDENTIFICATION OF A NOVEL TNFRSF11A (RANK) GENE VARIANT, PRODUCED THROUGH ALTERNATIVE SPLICING AND AFFECTING BREAST CANCER CELL SURVIVAL AND MIGRATION
104PTRIPTOLIDE INDUCES CELL DEATH OF BREAST CANCER CELLS VIA INHIBITION OF 14-3-3γ EXPRESSION
106PARACHIDONIC ACID INDUCES MMP-9 SECRETION IN NON-TUMORIGENIC MCF10A CELLS THROUGH A LIPOXYGENASE AND SRC DEPENDENT PATHWAY
107ER STATUS OF MOUSE MAMMARY TUMORS IN DIFFERENT MICROENVIRONMENTS
108DETECTION OF HUMAN PAPILLOMAVIRUS DNA IN BREAST CANCER IN MOROCCAN WOMAN
105PLONG-TERM EFFECTS OF EARLY PREGNANCY ON THE GENE EXPRESSION AND PROPERTIES OF MAMMARY EPITHELIAL CELL SUBPOPULATIONS IN MICE
109PCOMPARISON OF THE TRANSCRIPTIONAL RESPONSE TO FULVESTRANT AND OESTROGEN DEPRIVATION IN ER-POSITIVE BREAST CANCER IN VITRO AND IN VIVO
110PELEVATED EXPRESSION OF ZNF703 CONFERS TO TAMOXIFEN RESISTANCE IN BREAST CANCER
111FUNCTIONAL CORRELATION BETWEEN PHOSPHOLIPASE D, ERK AND PAXILLIN IN HUMAN BREAST CANCER MDA-MB-231 CELLS
112PANTITUMOR ACTIVITY OF FORETINIB IN BREAST CANCER XENOGRAFT MOUSE MODELS
113PINHIBITION OF NF- κB REGULATOR BCL-3 AS A NOVEL THERAPEUTIC APPROACH FOR HER2-POSITIVE BREAST CANCER
114PBREAST CANCER IN THE ELDERLY - THE IMPACT OF AGE ON TREATMENT
115PBREAST CANCER IN WOMEN : TOO YOUNG OR TOO OLD?
116POUTCOMES OF PATIENTS WITH BREAST CANCER BRAIN METASTASES : A SINGLE TERTIARY CENTER EXPERIENCE
117PEPIDEMIOLOGICAL CHARACTERISTICS OF BREAST CANCER IN MOROCCO
118PMETASTASIC BREAST CARCINOMA TO THE GALLBLADDER AND THE LOWER EYELID WITH NO MALIGNANT LESION IN THE BREAST : AN UNUSUAL CASE REPORT WITH A SHORT REVIEW OF LITERATURE
Author index
Subject index
Translational Research Index